Multimedia

Multimedia

Sound Bites and exclusive interviews with researchers, commentators, and experts in the field.

video

COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis

Ruben A. Mesa, MD, provides an update on the COMFORT-1 trial, which found that ruxolitinib has durable efficacy and long-term safety in patients with...
video

Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis

María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still...
video

What Was Hot at ASH 2015?

ASH Clinical News’ Editor-in-Chief Mikkael A. Sekeres, MD, MS, shares his highlights of the 2015 ASH Annual Meeting.
video

Multiple Advances in Multiple Myeloma

Sagar Lonial, MD, reviews the recent advances in the treatment of multiple myeloma, including how to sequence the newly approved myeloma drugs and their...
video

Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AML

Daniel Pollyea, MD, shares results from an early, phase Ib study of venetoclax plus decitabine or azacitidine in older patients with treatment-naïve acute myeloid...
video

Mogamulizumab May Be Effective in Relapsed/Refractory T-Cell Leukemia

Adrienne A. Phillips, MD, MPH, shares results seen with mogamulizumab in the largest randomized clinical trial of relapsed/refractory T-cell leukemia to date.
video

Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis

María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still...
video

Venetoclax Plus Hypomethylating Agents Leads to High Response Rates in Older Patients with AML

Daniel Pollyea, MD, shares results from an early, phase Ib study of venetoclax plus decitabine or azacitidine in older patients with treatment-naïve acute myeloid...
video

COMFORT: Five-Year Outcomes of Ruxolitinib in Patients With Myelofibrosis

Ruben A. Mesa, MD, provides an update on the COMFORT-1 trial, which found that ruxolitinib has durable efficacy and long-term safety in patients with...
video

CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?

Jeffrey Lancet, MD, discusses the findings from a phase III trial of CPX-351 versus 7+3 in older patients with high-risk, secondary acute myeloid leukemia
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.